Moderna(US:MRNA) Ge Long Hui·2025-10-23 08:21Core Viewpoint - Moderna's candidate vaccine mRNA-1647 for congenital cytomegalovirus (CMV) has failed to meet primary efficacy endpoints in Phase III clinical trials, leading the company to terminate its development [1]. Group 1: Clinical Trial Results - The Phase III trial involved approximately 7,500 women aged 16-40 from around 300 research centers across 13 countries [1]. - The vaccine demonstrated an efficacy rate for primary CMV infection of only 6% to 23%, significantly below the company's target [1]. Group 2: Market Reaction - Following the announcement, Moderna's stock price dropped over 4%, trading at $25.77 in pre-market [1]. - The closing price before the announcement was $26.85, reflecting a decline of $1.08 or 4.02% in pre-market trading [2].